Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 1
1971 1
1975 2
1977 2
1980 1
1981 2
1983 2
1986 1
1990 1
2000 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 2
2016 1
2017 3
2018 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
An evidence-based systematic review of annatto (Bixa orellana L.) by the Natural Standard Research Collaboration.
Ulbricht C, Windsor RC, Brigham A, Bryan JK, Conquer J, Costa D, Giese N, Guilford J, Higdon ER, Holmes K, Isaac R, Jingst S, Kats J, Peery L, Rusie E, Savinainen A, Schoen T, Stock T, Tanguay-Colucci S, Weissner W. Ulbricht C, et al. Among authors: bryan jk. J Diet Suppl. 2012 Mar;9(1):57-77. doi: 10.3109/19390211.2012.653530. J Diet Suppl. 2012. PMID: 22432803 Review. No abstract available.
An evidence-based systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration.
Ulbricht C, Brigham A, Bryan JK, Catapang M, Chowdary D, Costa D, Culwell S, D'Auria D, Giese N, Iovin R, Isaac R, Juturu V, Liu A, Mintzer M, Rusie E, Shaffer M, Windsor RC. Ulbricht C, et al. Among authors: bryan jk. J Diet Suppl. 2013 Sep;10(3):264-308. doi: 10.3109/19390211.2013.822631. Epub 2013 Aug 9. J Diet Suppl. 2013. PMID: 23931762 Review.
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL. Shayan G, et al. Among authors: bryan jk. Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23. Clin Cancer Res. 2018. PMID: 29061643 Free PMC article. Clinical Trial.
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Ferris RL, et al. Among authors: bryan jk. JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888. JAMA Oncol. 2018. PMID: 29931076 Free PMC article. Clinical Trial.
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG. Chow LQM, et al. Among authors: bryan jk. Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3. Clin Cancer Res. 2017. PMID: 27810904 Clinical Trial.
27 results